Ulrich Luecking

Progress towards a public chemogenomic set for protein kinases and a call for contributions

David H. Drewry, Carrow I. Wells, David Andrews et al. · PLoS ONE · 2017 · 170 citations · Full text

Pharmacy, Bioinformatics, Medicinal Chemistry +14

Molecular and pharmacodynamic characteristics of the novel multi-target tumor growth inhibitor ZK 304709

Gerhard Siemeister, Ulrich Luecking, C Wagner et al. · Biomedicine & Pharmacotherapy · 2006 · 59 citations

Medicine, Oncology, Pharmacology +12

Abstract 984: Identification of potent and highly selective PTEFb inhibitor BAY 1251152 for the treatment of cancer: from p.o. to i.v. application via scaffold hops

Ulrich Luecking, Arne Scholz, Dirk Kosemund et al. · Cancer Research · 2017 · 28 citations

Medicine, Oncology, Pharmacology +16

Progress Towards a Public Chemogenomic Set for Protein Kinases and a Call for Contributions

David H. Drewry, Carrow I. Wells, David Andrews et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2017 · 24 citations · Full text

Pharmacy, Bioinformatics, Medicinal Chemistry +14

Abstract 3022: BAY 1143572, a first-in-class, highly selective, potent and orally available inhibitor of PTEFb/CDK9 currently in Phase I, shows convincing anti-tumor activity in preclinical models of acute myeloid leukemia (AML)

Arne Scholz, Thomas Oellerich, Akhtar Hussain et al. · Cancer Research · 2016 · 18 citations

Medicine, Oncology, Pharmacology +15